Compare XPON & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPON | XBIO |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 6.9M |
| IPO Year | 2022 | N/A |
| Metric | XPON | XBIO |
|---|---|---|
| Price | $0.51 | $3.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 158.7K | 10.1K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.63 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,651,870.00 | N/A |
| Revenue This Year | N/A | $2.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 71.59 | N/A |
| 52 Week Low | $0.45 | $1.90 |
| 52 Week High | $5.50 | $13.93 |
| Indicator | XPON | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 42.24 | 54.05 |
| Support Level | $0.49 | $2.94 |
| Resistance Level | $0.58 | $3.44 |
| Average True Range (ATR) | 0.03 | 0.16 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 48.93 | 48.30 |
Expion360 Inc focuses on the design, assembly, manufacturing, and sale of lithium iron phosphate (LiFePO4) batteries and related accessories for RV, marine, and industrial applications. Its high-performance battery solutions are designed for high energy density and a compact footprint, supported by engineering and intellectual property to enhance safety, quality, and performance. The company also engages in product design, development, and collaboration to strengthen customer relationships. It serves dealers, wholesalers, private-label customers, and OEMs, who distribute its products to end consumers. Its segment is Energy Storage (ES), providing lithium-based energy solutions backed by durable materials, optimized internal structures, and responsive customer service.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.